IndustryCompany release

Egetis board backs ANI's SEK 5.3bn cash offer for EMCITATE developer

🇺🇸 Ani Pharmaceuticals Inc (ANIP) · Thu 05 Nov 2026

Egetis Therapeutics' board has unanimously recommended ANI Pharmaceuticals' SEK 11.25-per-share bid, weeks after the US approval of EMCITATE for MCT8 deficiency.

The board of Egetis Therapeutics on 5 November 2026 unanimously recommended that shareholders accept a public cash offer from ANI Pharmaceuticals. The recommendation also extends to holders of the company's convertibles and warrants.

ANI is offering SEK 11.25 per share, which values the transaction at about SEK 5.3 billion. The offer is conditional on acceptance by more than 90 percent of holders, as well as on regulatory and competition clearances.

Shareholders representing about 42.2 percent have already committed to accept the offer, according to the information available.

The bid follows the US Food and Drug Administration's approval of Egetis' EMCITATE on 28 September 2026. The medicine is indicated for MCT8 deficiency, also known as Allan–Herndon–Dudley syndrome. The Egetis board said it expects ANI to accelerate the product's US launch.

What it means for your team

  • Market-access teams should watch for any change in launch timing and US commercial plans for EMCITATE once the deal progresses, as the Egetis board expects a faster rollout under ANI.
  • Regulatory and competition clearances are explicit conditions, so completion depends on approvals as well as the 90 percent acceptance threshold.
  • The transaction shows continued acquirer interest in newly approved rare-disease therapies.

Company's press release (SEC filing): Ani Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Ani Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →